Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (16758)	3/7/1998 11:19:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

FUGAZI, The vast majority of Biotech therapeutics are injected drugs that initially bind to receptors for interferons, interleukins, and growth factors. Insulin binds to the insulin receptor to treat Type I and Type II diabetes. Aldesleukin binds to the IL-2 receptor to treat various cancers and it may benefit HIV+ patients. Epogen binds to the erythropoeitin receptor to stimulate red blood cell production and is used in cancer chemotherapy. Neupogen binds to the granulocyte colony stimulating factor receptor to stimulate white blood cell production and recently it has been shown to block HIV infection. Betaseron and Avonex bind to another interleukin receptor to treat MS. Myotropin binds to the insulin-like growth factor receptor to treat Lou Gehrigs Disease (ALS). Leptin binds to the leptin receptor to modulate obesity and puberty. This result is VERY big.